Smokeless tobacco is any tobacco product used by placing it in the mouth or nose rather than burning and inhaling it. About 5.2 million U.S. adults use smokeless tobacco, representing roughly 2% of the adult population. Despite the absence of smoke, these products deliver nicotine and contain dozens of carcinogens, including some of the most potent cancer-causing compounds found in any consumer product.
Types of Smokeless Tobacco
Smokeless tobacco comes in several distinct forms, each used differently.
- Chewing tobacco is cured tobacco sold as loose leaf, plug, or twist. Users place a wad between the cheek and gum and chew it intermittently.
- Moist snuff (dip) is finely cut tobacco, sold loose or in small pouches, placed between the lip and gum. This is the most popular form in the United States.
- Dry snuff is powdered tobacco typically sniffed through the nostrils rather than placed in the mouth.
- Snus is a Scandinavian-origin product similar to moist snuff but processed differently. It comes loose or in pouches and sits between the upper lip and gum.
- Dissolvable tobacco products are made from ground or powdered tobacco compressed into lozenges, strips, or sticks that dissolve in the mouth.
What’s Actually in It
Smokeless tobacco contains at least six broad categories of carcinogens. The most abundant and powerful are tobacco-specific nitrosamines, which form naturally when tobacco alkaloids break down during curing, fermentation, and aging. Two of these compounds, known by their abbreviations NNN and NNK, have especially strong cancer-causing effects and are present in every smokeless tobacco product tested.
Beyond nitrosamines, smokeless tobacco contains polycyclic aromatic hydrocarbons (the same class of compounds found in charred meat and diesel exhaust), formaldehyde, acetaldehyde, and heavy metals including cadmium, uranium, and polonium. The exact concentration of these chemicals varies widely by product and brand, which is one reason different types of smokeless tobacco carry different levels of risk.
How Nicotine Absorption Compares to Cigarettes
Smokeless tobacco delivers nicotine through the lining of the mouth or nose rather than through the lungs. The absorption is slower but can be just as substantial. A typical dose from a pouch or dip can match or exceed the total nicotine exposure from a single cigarette, depending on the product’s nicotine content and how long it stays in the mouth. Lower-dose products deliver less nicotine than a cigarette, while higher-dose products deliver significantly more. Peak nicotine levels in the blood tend to be lower with oral products than with smoking, but the nicotine stays elevated longer because absorption continues as long as the tobacco remains in place.
This sustained delivery pattern makes smokeless tobacco highly addictive. The FDA requires packages to carry the warning: “Smokeless tobacco is addictive.”
Oral Health Effects
The mouth takes the most direct hit. Smokeless tobacco users develop leukoplakia, white patches on the inner cheeks or gums, at roughly six times the rate of non-users. These lesions form at the exact spot where users habitually place their tobacco and are considered potentially precancerous. Among daily snus users in one Norwegian study, nearly 80% showed visible changes to the tissue lining their mouths.
Gum recession is another consistent finding. Smokeless tobacco users have about 1.7 times the odds of receding gums compared to non-users. The type of product matters: one study found gum recession in 23.5% of people using loose snus versus only 2.9% of those using pouched snus, likely because loose tobacco creates more direct friction and chemical contact with gum tissue.
Tooth decay and tooth loss round out the picture. Many smokeless products contain sweeteners and flavoring agents that promote cavities, and the coarse particles in some products physically wear down tooth enamel. Tobacco users experience a 67% higher rate of tooth loss compared to non-users.
Cancer and Cardiovascular Risks
Smokeless tobacco use is linked to cancers of the mouth, esophagus, and pancreas. The primary driver is chronic exposure to tobacco-specific nitrosamines, which damage DNA in the tissues they contact. Because the product sits directly against oral tissue for extended periods, the mouth and throat receive concentrated exposure.
The cardiovascular picture is more nuanced. A large meta-analysis found that smokeless tobacco users overall had a modest, not statistically significant increase in coronary heart disease risk. But fatal heart disease told a different story: snus and snuff users had a 37% higher risk of dying from heart disease. The risk was most pronounced in European users, where the association with fatal coronary heart disease was statistically significant.
Snus vs. American Snuff: A Key Difference
Not all smokeless products are equally harmful. Swedish snus is made from low-nitrate tobacco and is pasteurized (heat-treated) rather than fermented. This processing difference matters because fermentation is the stage where many carcinogenic nitrosamines form. As a result, snus contains significantly lower levels of cancer-causing nitrosamines compared to American-style moist snuff.
This does not make snus safe. It still causes oral lesions, gum recession, and nicotine dependence. But it helps explain why Sweden, where snus dominates the smokeless market, shows different patterns of tobacco-related disease than countries where fermented products are more common. The FDA still requires all smokeless tobacco products to carry the warning: “This product is not a safe alternative to cigarettes.”
Who Uses Smokeless Tobacco
In 2021, about 2.1% of U.S. adults (5.2 million people) reported current smokeless tobacco use. Use is heavily skewed toward men and is more common in rural areas and certain occupational groups. Among youth, 2024 data shows 1.5% of high school students and 0.8% of middle school students currently use smokeless tobacco, for an overall youth rate of 1.2%.
Quitting Smokeless Tobacco
Quitting smokeless tobacco presents its own challenges, partly because the slow, sustained nicotine delivery creates a dependence pattern distinct from cigarette addiction. Not every cessation tool that works for smoking works equally well here.
A Cochrane review of cessation methods found that nicotine lozenges increased quit rates by about 36%, and the prescription medication varenicline increased quit rates by about 34%. Nicotine patches and nicotine gum, staples of smoking cessation, did not show a clear benefit for smokeless tobacco users in pooled study results. The antidepressant bupropion, another common smoking cessation aid, also showed no detectable benefit.
Behavioral support proved surprisingly effective. Telephone counseling roughly doubled the chances of quitting. When telephone support was combined with an oral health examination where users could see the damage to their own mouth tissue, the combination more than doubled abstinence rates across four studies. Seeing the physical consequences of use, paired with ongoing support, appears to be one of the most consistently helpful approaches for people trying to stop.